'Cardiovascular risk' diaporamas de présentation

??????? ????????

??????? ????????. ?"? ?? ??? ddkeret@zahav.net.il. Historical Context : 1920 Kylin- HTN, Hyperglycemia, Gout 1947 Vague - Upper body adiposity=Android/ male type obesity goes with DM + CHD. 1988 Reaven- Syndrome X : glucose & insulin metab + HTN + dyslipidemia (not obesity yet)

1.19k views • 86 slides

Chronic Kidney Disease The Recognized Epidemic

Chronic Kidney Disease The Recognized Epidemic. Shagun Chopra m.D. Director of dialysis &Transplant NMcsd Assistant professor of medicine ucsd Assistant professor of medicine usuhs. Outline. ESRD What is CKD? Epidemiology of CKD? What does CKD predict?

970 views • 81 slides

The New Prevention Guidelines

The New Prevention Guidelines. David W K abel MD, FACC December 4, 2013. New AHA/ACC Guidelines. Treatment of Blood Cholesterol to Reduce Cardiovascular Risk Management of Overweight and Obesity in Adults Lifestyle Management to Reduce Cardiovascular Risk Assessment of Cardiovascular Risk.

857 views • 66 slides

In The Name of God

In The Name of God. Subclinical Cushings Syndrome Sheila Afsharian MD Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences. Questions. What is SCS? What is the natural consequence of SCS in patients?

1.15k views • 65 slides

Exercise Prescription from Eight to Eighty

Activity. Exercise Prescription from Eight to Eighty. Brian K. Unwin, M.D. Anthony Beutler, M.D. Jeff Goodie, Ph.D. Department of Family Medicine Uniformed Services University Bethesda, MD. Overview. Obesity & chronic disease epidemic Motivational counseling technique

668 views • 54 slides

2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults

2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults.

690 views • 46 slides

Research Associates Programs

583 views • 45 slides

Estrogen and Coronary Heart Disease

Estrogen and Coronary Heart Disease. by Brad Jones. Case Presentation. 56 y/o WF PMH significant for TAH on Premarin for 10 years. Cardiovascular risk factors include history of early MI in father. No documented coronary disease.

844 views • 43 slides

LINEE GUIDA, KDIGO E DIALISI PERITONEALE

LINEE GUIDA, KDIGO E DIALISI PERITONEALE. GIANCARLO MARINANGELI U.O.C. NEFROLOGIA E DIALISI GIULIANOVA . KDOQI and KDIGO. NKF- Kidney Disease Outcome Quality Initiative. 2003 Targets for treatment. Kidney Disease Improving Global Outcomes. 2009 Range of risks.

1.71k views • 42 slides

Preoperative Nursing

549 views • 36 slides

Plasma Concentration of TNF- ? and Risk of Recurrent Coronary Events

459 views • 32 slides

stroke

Dr Farzadfard. stroke. Stroke types. Infarcts Artery Vein Hemorrhages ICH IVH SAH. Presentation. Abrupt Onset Fit the distribution of a single vascular territory

561 views • 30 slides

387 views • 29 slides

Risk Stratification in CVD Prevention How to Identify Cardiovascular Risk in the Office

Risk Stratification in CVD Prevention How to Identify Cardiovascular Risk in the Office. Dr. Thomas G. Allison Cardiovascular Diseases and Internal Medicine Mayo Clinic Rochester, MN. Clinically-Based CVD Prevention. Risk assessment for all patients

784 views • 28 slides

Using IT To Reduce The Stress Of A Diabetes Clinic

Using IT To Reduce The Stress Of A Diabetes Clinic. What Happens at a Diabetes Clinic?. Screening for complications Identification of problems Intervention Prescribing Referral for advice. Why can diabetes clinics be difficult?. History Diabetes clinics are busy

584 views • 26 slides

Correlates of Social Position in Brain Serotonergic Function

339 views • 26 slides

A FACES Initiative To Prevent Cardiovascular Diseases In Nyanza Province, Kenya

A FACES Initiative To Prevent Cardiovascular Diseases In Nyanza Province, Kenya Heri kuzuia kuliko kuuguza. Overview of the presentation. Cardiovascular Disease (CVD) in Kenya Geography and Demography of Target Groups CardioCulture Program Outreach Plan Budget

353 views • 25 slides

Alcohol and violence in a medical context

456 views • 24 slides

April 12, 2007

Testimony of Sidney M. Wolfe M.D. Director, Health Research Group of Public Citizen FDA Arthritis Advisory Committee Meeting on Etoricoxib (Arcoxia) for Treatment of Osteoarthritis. April 12, 2007. Introduction. The consideration of approval of etoricoxib involves three outcome variables:

403 views • 20 slides

SJ Nicholls, CM Ballantyne , JJP Kastelein , A Taylor, A Gordon, J Johansson, K Wolski , M Borgman and SE Nissen

Results of the First Major Clinical Trial of An Oral Agent Inducing ApoA -I Synthesis: A New Approach to Raising HDL and CV Risk Modification. SJ Nicholls, CM Ballantyne , JJP Kastelein , A Taylor, A Gordon, J Johansson, K Wolski , M Borgman and SE Nissen. The ASSERT Study.

735 views • 18 slides